Compile Data Set for Download or QSAR
Report error Found 76 Enz. Inhib. hit(s) with all data for entry = 11471
TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618656(US11760761, Compound D-3)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618657(US11760761, Compound D-4)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618658(US11760761, Compound D-5)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618659(US11760761, Compound D-6)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618652(US11760761, Compound C-14)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618653(US11760761, Compound C-15)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618654(US11760761, Compound D-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618655(US11760761, Compound D-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618664(US11760761, Compound D-11)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618665(US11760761, Compound D-12)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618666(US11760761, Compound D-13)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618667(US11760761, Compound D-14)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618660(US11760761, Compound D-7)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618661(US11760761, Compound D-8)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618662(US11760761, Compound D-9)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618663(US11760761, Compound D-10)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618640(US11760761, Compound C-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618641(US11760761, Compound C-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618642(US11760761, Compound C-3)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618643(US11760761, Compound C-4)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618572(US11760761, Compound B-1 | US11760761, Compound A-...)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618637(US11760761, Compound B-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618638(US11760761, Compound B-3)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618639(US11760761, Compound B-4)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618648(US11760761, Compound C-9)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618649(US11760761, Compound C-10)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618650(US11760761, Compound C-11)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618651(US11760761, Compound C-12)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618644(US11760761, Compound C-5)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618645(US11760761, Compound C-6)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618646(US11760761, Compound C-7)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618647(US11760761, Compound C-8)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618688(US11760761, Compound H-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618689(US11760761, Compound H-3)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618690(US11760761, Compound H-4)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618691(US11760761, Compound I-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618684(US11760761, Compound G-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618685(US11760761, Compound G-5)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618686(US11760761, Compound G-6)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618687(US11760761, Compound H-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618696(US11760761, Compound H-6)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618697(US11760761, Compound K-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618698(US11760761, Compound K-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618692(US11760761, Compound J-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618693(US11760761, Compound J-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618694(US11760761, Compound J-3)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618695(US11760761, Compound H-5)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618672(US11760761, Compound D-19)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618673(US11760761, Compound E-1)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Aligos Therapeutics

US Patent
LigandPNGBDBM618674(US11760761, Compound E-2)
Affinity DataIC50: 10nMAssay Description:Compounds to be tested were serially diluted in DMSO, and further diluted in assay buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 0.005% Tween 20, BSA 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/29/2023
Entry Details
US Patent

Displayed 1 to 50 (of 76 total ) | Next | Last >>
Jump to: